UY35586A - Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades - Google Patents

Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades

Info

Publication number
UY35586A
UY35586A UY0001035586A UY35586A UY35586A UY 35586 A UY35586 A UY 35586A UY 0001035586 A UY0001035586 A UY 0001035586A UY 35586 A UY35586 A UY 35586A UY 35586 A UY35586 A UY 35586A
Authority
UY
Uruguay
Prior art keywords
pirazolopirrolidine
diseases
derivatives
treatment
present
Prior art date
Application number
UY0001035586A
Other languages
English (en)
Inventor
Blank Jutta
Bordas Vincent
Rueeger Heinrich
Vaupel Andrea
Cotesta Simona
Guagnano Vito
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY35586A publication Critical patent/UY35586A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona un compuesto de la fórmula (I) o una sal farmacéuticamente aceptable del mismo un método para fabricar los compuesto de la invención, y sus usos terapéuticos. La presente invención además proporciona una combinación de agentes farmacológicamente activos y una composición farmacéutica.
UY0001035586A 2013-05-27 2014-05-26 Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades UY35586A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13169364 2013-05-27
EP13177673 2013-07-23

Publications (1)

Publication Number Publication Date
UY35586A true UY35586A (es) 2014-12-31

Family

ID=50979827

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035586A UY35586A (es) 2013-05-27 2014-05-26 Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades

Country Status (37)

Country Link
US (2) US8975417B2 (es)
EP (1) EP3004110B1 (es)
JP (1) JP6181862B2 (es)
KR (1) KR20160012196A (es)
CN (1) CN105408335B (es)
AU (1) AU2014272776C1 (es)
BR (1) BR112015029512A8 (es)
CA (1) CA2913223A1 (es)
CL (1) CL2015003395A1 (es)
CR (1) CR20150628A (es)
CU (1) CU24350B1 (es)
CY (1) CY1119490T1 (es)
DK (1) DK3004110T3 (es)
EA (1) EA029515B1 (es)
EC (1) ECSP15053445A (es)
ES (1) ES2651843T3 (es)
HK (1) HK1216251A1 (es)
HR (1) HRP20171613T1 (es)
HU (1) HUE036674T2 (es)
IL (1) IL242610A0 (es)
LT (1) LT3004110T (es)
ME (1) ME02906B (es)
MX (1) MX364205B (es)
NO (1) NO3004110T3 (es)
PE (1) PE20160005A1 (es)
PH (2) PH12015502628A1 (es)
PL (1) PL3004110T3 (es)
PT (1) PT3004110T (es)
RS (1) RS56522B1 (es)
SG (1) SG11201509474SA (es)
SI (1) SI3004110T1 (es)
SV (1) SV2015005115A (es)
TN (1) TN2015000505A1 (es)
UA (1) UA116017C2 (es)
UY (1) UY35586A (es)
WO (1) WO2014191896A1 (es)
ZA (1) ZA201508259B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013175417A1 (en) 2012-05-24 2013-11-28 Novartis Ag Pyrrolopyrrolidinone compounds
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
EP2935253B1 (en) 2012-12-21 2018-08-01 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
UA119848C2 (uk) 2013-03-15 2019-08-27 Інсайт Холдинґс Корпорейшн Трициклічні гетероцикли як інгібітори білків бет
EP3004108B1 (en) * 2013-05-28 2017-10-18 Novartis AG Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
JP6599852B2 (ja) 2013-06-21 2019-10-30 ゼニス・エピジェネティクス・リミテッド ブロモドメイン阻害剤としての新規の置換された二環式化合物
ES2806135T3 (es) 2013-06-21 2021-02-16 Zenith Epigenetics Ltd Nuevos inhibidores de bromodominios bicíclicos
JP2016523964A (ja) 2013-07-08 2016-08-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｂｅｔタンパク質阻害剤としての三環式複素環
CN105593224B (zh) 2013-07-31 2021-05-25 恒元生物医药科技(苏州)有限公司 作为溴结构域抑制剂的新型喹唑啉酮类化合物
ES2930305T3 (es) 2013-10-18 2022-12-09 Celgene Quanticel Res Inc Inhibidores del bromodominio
WO2015081203A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
LT3134403T (lt) 2014-04-23 2020-05-11 Incyte Corporation 1h-pirolo[2,3-c]piridin-7(6h)-onai ir pirazolo[3,4-c]piridin-7(6h)-onai, kaip bet baltymų inhibitoriai
US9527864B2 (en) 2014-09-15 2016-12-27 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
US10179125B2 (en) 2014-12-01 2019-01-15 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
CA2966298A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
JP2017537946A (ja) 2014-12-11 2017-12-21 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての置換複素環
CA2966450A1 (en) 2014-12-17 2016-06-23 Olesya KHARENKO Inhibitors of bromodomains
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
KR20180039117A (ko) 2015-08-11 2018-04-17 네오메드 인스티튜트 아릴-치환된 디히드로퀴놀리논, 그의 제조법 및 제약으로서의 그의 용도
WO2017024406A1 (en) 2015-08-11 2017-02-16 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
CN108137539B (zh) 2015-08-12 2022-01-11 尼奥迈德研究所 取代的苯并咪唑、它们的制备和它们作为药物的用途
WO2017066876A1 (en) 2015-10-21 2017-04-27 Neomed Institute Substituted imidazopyridines, their preparation and their use as pharmaceuticals
TW201722966A (zh) 2015-10-29 2017-07-01 英塞特公司 Bet蛋白質抑制劑之非晶固體形式
WO2017127930A1 (en) * 2016-01-28 2017-08-03 Neomed Institute Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals
MX2018009870A (es) 2016-02-15 2018-11-29 Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh Inhibidores de taf1 para la terapia del cancer.
PL3458101T3 (pl) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
AR109250A1 (es) * 2016-06-09 2018-11-14 Acetylon Pharmaceuticals Inc Métodos de uso y combinaciones farmacéuticas de inhibidores de hdac con inhibidores de proteínas bet
EP3472157B1 (en) 2016-06-20 2023-04-12 Incyte Corporation Crystalline solid forms of a bet inhibitor
UA125520C2 (uk) 2016-08-31 2022-04-13 Джянгсу Хенгруй Медісін Ко., Лтд. Похідні оксопіколінаміду, спосіб їх отримання та їх фармацевтичне застосування
JP2020511401A (ja) 2016-11-14 2020-04-16 チェム−フォルシュングスツェントルン フュル モレクラーレ メディツィン ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌の治療法のためのｂｒｄ４阻害剤と葉酸代謝拮抗薬との組み合わせ物
CN109232301B (zh) * 2018-10-15 2021-01-01 天津希恩思生化科技有限公司 一种四异丙基肼的制备方法
JP2022053557A (ja) * 2019-02-08 2022-04-06 マルホ株式会社 ピリドン誘導体
EP3997091A1 (en) * 2019-07-12 2022-05-18 Scenic Immunology B.V. N-substituted-3,4-(fused 5-ring)-5-phenyl-pyrrolidine-2-one compounds as inhibitors of isoqc and/or qc enzyme
TW202126638A (zh) 2019-09-30 2021-07-16 日商協和麒麟股份有限公司 Bet分解劑
CN112625036A (zh) * 2019-10-08 2021-04-09 上海海和药物研究开发股份有限公司 一类具有brd4抑制活性的化合物、其制备方法及用途
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN117157296A (zh) * 2021-01-21 2023-12-01 首都医科大学附属北京天坛医院 Fpr1的调节剂及其使用方法
EP4380933A1 (en) 2021-08-02 2024-06-12 Syngenta Crop Protection AG Microbiocidal pyrazole derivatives
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
EP4447682A1 (en) 2021-12-17 2024-10-23 Syngenta Crop Protection AG Microbiocidal pyrazole derivatives
WO2023233130A1 (en) 2022-05-30 2023-12-07 AdoRx Therapeutics Limited Cd73 inhibitor compounds
WO2024068947A1 (en) 2022-09-30 2024-04-04 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
WO2024156886A1 (en) 2023-01-27 2024-08-02 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
WO2024160801A1 (en) 2023-02-01 2024-08-08 Syngenta Crop Protection Ag Fungicidal compositions

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508300A (en) 1994-01-14 1996-04-16 Pfizer Inc. Dihydro pyrazolopyrroles, compositions and use
PT1320531E (pt) 2000-08-10 2010-10-27 Pfizer Italia Srl Biciclo-pirazoles activos como inibidores da cinase, processo para a sua preparação e composições farmacêuticas compreendendo estes
HU228844B1 (en) * 2001-05-24 2013-06-28 Lilly Co Eli Pyrrole derivatives and pharmaceutical compositions containing them
DE60225719T2 (de) 2001-12-18 2009-04-23 F. Hoffmann-La Roche Ag Cis-2,4,5- triphenyl-imidazoline und ihre verwendung bei der behandlung von tumoren
US20060189511A1 (en) 2002-05-13 2006-08-24 Koblish Holly K Method for cytoprotection through mdm2 and hdm2 inhibition
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
KR20080027969A (ko) 2004-05-18 2008-03-28 에프. 호프만-라 로슈 아게 신규 ｃｉｓ-이미다졸린
US20060069085A1 (en) 2004-09-28 2006-03-30 Rulin Zhao Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
EP1833807A1 (en) 2005-01-05 2007-09-19 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
WO2007068637A1 (en) 2005-12-12 2007-06-21 Nerviano Medical Sciences S.R.L. Substituted pyrrolo-pyrazole derivatives active as kinase inhibitors
WO2007096334A1 (en) 2006-02-24 2007-08-30 Pfizer Italia Srl Pyrrolopyrrolones active as kinase inhibitors
WO2008034039A2 (en) 2006-09-15 2008-03-20 Nexuspharma Inc. Novel tetrahydro-isoquinolines
KR20100016076A (ko) 2007-03-30 2010-02-12 시오노기 앤드 컴파니, 리미티드 신규 피롤리논 유도체 및 그것을 함유하는 의약 조성물
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
UY31982A (es) 2008-07-16 2010-02-26 Boehringer Ingelheim Int Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas
EP2336109A4 (en) 2008-09-25 2012-05-02 Shionogi & Co NOVEL PYRROLINONE DERIVATIVE AND DRUG COMPOSITION CONTAINING THE SAME
US20120208204A1 (en) 2009-06-03 2012-08-16 The Brigham And Women's Hospital, Inc. Compositions and Methods for Inhibiting Tumor Growth
GB0919423D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
EP2569429A4 (en) * 2010-05-14 2013-09-25 Dana Farber Cancer Inst Inc COMPOSITIONS AND METHOD OF METABOLIC MODULATION
ES2526671T3 (es) 2010-06-22 2015-01-14 Glaxosmithkline Llc Compuestos de benzotriazoldiazepina inhibidores de bromodominios
US20120065210A1 (en) 2010-09-15 2012-03-15 Xin-Jie Chu Substituted hexahydropyrrolo[1,2-c]imidazolones
GB201016880D0 (en) 2010-10-07 2010-11-17 Riotech Pharmaceuticals Ltd Phosphodiesterase inhibitors
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
EP2705039B1 (en) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2721031B1 (en) 2011-06-17 2016-01-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012175520A1 (en) 2011-06-20 2012-12-27 Novartis Ag Hydroxy substituted isoquinolinone derivatives
US8859586B2 (en) 2011-06-20 2014-10-14 Novartis Ag Cyclohexyl isoquinolinone compounds
GB2492950A (en) 2011-07-11 2013-01-23 Cambridge Consultants Measuring a luminescent property of a sample using a dual-modulated excitation beam
WO2013033270A2 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same
JP5992054B2 (ja) 2011-11-29 2016-09-14 ノバルティス アーゲー ピラゾロピロリジン化合物
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
WO2013175417A1 (en) 2012-05-24 2013-11-28 Novartis Ag Pyrrolopyrrolidinone compounds

Also Published As

Publication number Publication date
BR112015029512A8 (pt) 2019-12-17
ES2651843T3 (es) 2018-01-30
SV2015005115A (es) 2018-04-04
LT3004110T (lt) 2017-11-10
CA2913223A1 (en) 2014-12-04
PH12015502628B1 (en) 2016-03-07
PL3004110T3 (pl) 2017-12-29
CY1119490T1 (el) 2018-03-07
BR112015029512A2 (pt) 2017-07-25
PH12018501807A1 (en) 2019-03-25
TN2015000505A1 (en) 2017-04-06
DK3004110T3 (da) 2017-11-06
ECSP15053445A (es) 2017-10-31
HK1216251A1 (zh) 2016-10-28
US20140349990A1 (en) 2014-11-27
CU24350B1 (es) 2018-06-05
IL242610A0 (en) 2016-02-01
SG11201509474SA (en) 2015-12-30
MX364205B (es) 2019-04-16
RS56522B1 (sr) 2018-02-28
PT3004110T (pt) 2017-11-08
KR20160012196A (ko) 2016-02-02
CN105408335A (zh) 2016-03-16
JP2016520117A (ja) 2016-07-11
MX2015016416A (es) 2016-03-03
AU2014272776A1 (en) 2015-12-03
AU2014272776B2 (en) 2016-11-10
EA029515B1 (ru) 2018-04-30
US20160095843A1 (en) 2016-04-07
EP3004110A1 (en) 2016-04-13
CN105408335B (zh) 2017-11-17
NO3004110T3 (es) 2017-12-23
UA116017C2 (uk) 2018-01-25
PH12015502628A1 (en) 2016-03-07
SI3004110T1 (sl) 2017-11-30
AU2014272776C1 (en) 2017-06-01
HRP20171613T1 (hr) 2017-12-01
EP3004110B1 (en) 2017-07-26
ZA201508259B (en) 2017-01-25
ME02906B (me) 2018-04-20
CU20150163A7 (es) 2016-05-30
CR20150628A (es) 2016-01-29
WO2014191896A1 (en) 2014-12-04
CL2015003395A1 (es) 2016-05-20
EA201592250A1 (ru) 2016-05-31
PE20160005A1 (es) 2016-01-21
JP6181862B2 (ja) 2017-08-16
US8975417B2 (en) 2015-03-10
HUE036674T2 (hu) 2018-07-30

Similar Documents

Publication Publication Date Title
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
UY34974A (es) Piridazina 1,4 disustituida, análogos de la misma y métodos para tratar las enfermedades relacionadas con deficiencia del smn
SV2016005351A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
CO6781541A2 (es) Derivados glucósidos y usos de los mismos
UY36124A (es) Derivados de carboxamida
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
UY35209A (es) Compuestos tricíclicos
CL2017000845A1 (es) Inhibidores de gingipaina de lisina
UY36123A (es) Derivados de carboxamida
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
UY35211A (es) Compuestos tricíclicos
CL2020001277A1 (es) Derivados de piridinona y su uso como inhibidores selectivos de alk-2.
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
UY33806A (es) ?compuestos novedosos de imidazoquinolina, composiciones que los contienen y su uso en el tratamiento de enfermedades mediadas por tlr7?
CU20160170A7 (es) Derivados de carboxamida
UY35672A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211206